ZA202210355B - Compositions and therapeutic uses of cannabidiol - Google Patents

Compositions and therapeutic uses of cannabidiol

Info

Publication number
ZA202210355B
ZA202210355B ZA2022/10355A ZA202210355A ZA202210355B ZA 202210355 B ZA202210355 B ZA 202210355B ZA 2022/10355 A ZA2022/10355 A ZA 2022/10355A ZA 202210355 A ZA202210355 A ZA 202210355A ZA 202210355 B ZA202210355 B ZA 202210355B
Authority
ZA
South Africa
Prior art keywords
cannabidiol
therapeutic agent
pharmaceutical composition
inflammation induced
covid
Prior art date
Application number
ZA2022/10355A
Other languages
English (en)
Inventor
Manit Patel
Peter Charles Ruben
Mohamed Amin Fouda
Mohammad-Reza Ghovanloo
Vishal Anant Jadhav
Dana A Page
Koushik Choudhury
Rusinova Radda
Tejas Phaterpekar
Original Assignee
Dr Merchant Shreema
Manit Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Merchant Shreema, Manit Patel filed Critical Dr Merchant Shreema
Publication of ZA202210355B publication Critical patent/ZA202210355B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/10355A 2020-02-19 2022-09-19 Compositions and therapeutic uses of cannabidiol ZA202210355B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021007184 2020-02-19
IN202021013770 2020-03-29
PCT/IN2021/050159 WO2021165992A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Publications (1)

Publication Number Publication Date
ZA202210355B true ZA202210355B (en) 2024-02-28

Family

ID=77391770

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/10355A ZA202210355B (en) 2020-02-19 2022-09-19 Compositions and therapeutic uses of cannabidiol

Country Status (9)

Country Link
US (1) US20230123654A1 (https=)
EP (1) EP4106870A4 (https=)
JP (1) JP2023516284A (https=)
CN (1) CN115916336A (https=)
AU (1) AU2021223191A1 (https=)
CA (1) CA3171890A1 (https=)
IL (1) IL295753A (https=)
WO (1) WO2021165992A1 (https=)
ZA (1) ZA202210355B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
WO2022122904A1 (en) * 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
JPWO2024043242A1 (https=) * 2022-08-23 2024-02-29

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087374B2 (en) * 2003-06-26 2006-08-08 The Research Foundation Of State University Of New York Screen for sodium channel modulators
MX376077B (es) * 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
LT6486B (lt) * 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
IL262713B2 (en) * 2016-05-02 2024-07-01 Stero Biotechs Ltd Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US20210085801A1 (en) * 2017-12-12 2021-03-25 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
KR102632946B1 (ko) * 2018-01-13 2024-02-05 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients

Also Published As

Publication number Publication date
AU2021223191A1 (en) 2022-10-13
CN115916336A (zh) 2023-04-04
IL295753A (en) 2022-10-01
JP2023516284A (ja) 2023-04-19
US20230123654A1 (en) 2023-04-20
WO2021165992A1 (en) 2021-08-26
EP4106870A4 (en) 2024-04-10
EP4106870A1 (en) 2022-12-28
CA3171890A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
ZA202210355B (en) Compositions and therapeutic uses of cannabidiol
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
BR112021015109A2 (pt) Conjugado de fármaco-ligante duplo e uso do mesmo
CR6630A (es) Compuestos de indazol, compuestos farmacologicos y metodos para la intervencion o inhibicion de la proliferacion celular
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BR112015009504A2 (pt) inibidores de rock
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BR112020019875A8 (pt) composições tópicas para alívio da dor
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
MY207469A (en) Therapeutic compounds
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
BR112023002295A2 (pt) Terapia de combinação
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
BR112022006394A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
PE20250835A1 (es) Composiciones y uso de la tirzepatida
MX2021011746A (es) Formulacion de combinacion triple de dosis baja.
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres